Learning Objectives:

  1. Understand the mechanism of action for FcRn antagonists
  2. understand the evidence to date supporting use of FcRn antagonists for myasthenia gravis
  3. know potential safety risks associated with FcRn antagonists
Session date: 
Thursday, December 17, 2020 - 7:30am to 8:30am
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Jeffrey Guptill